TheraRadar
Data updated: May 26, 2026

CEFIXIME

Infectious Disease Approved 2015-04-14

Cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections Otitis Media Pharyngitis and Tonsillitis Acute Exacerbations of Chronic Bronchitis Uncomplicated Gonorrhea (cervical/urethral) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs, cefixime...

Source: FDA Label • ALKEM LABS LTD
8
Indications
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2015-04-14
Routes
ORAL
Dosage Forms
CAPSULE, FOR SUSPENSION, TABLET

CEFIXIME Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
16 FDA actions from 2015 to 2026
May 2026 ORIGINAL
Update
Mar 2026 ORIGINAL
Update
Dec 2024 ORIGINAL
Update

What CEFIXIME Treats

8 FDA approvals

Originally approved for its first indication in 2015 . Covers 8 distinct patient populations.

  • Other (8)
📋

Clinical Trial Registry

9 trials
Trial Sponsor ID Phase Status Title
NCT05294588 21-0498 DMID 21-0018, U01AI162457-01 Ph 2 completed Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae
NCT04349826 ACT-South Asia 25NP Ph 4 completed The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
NCT06090565 9937 Ph 4 completed Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea
NCT03840811 results posted 09-0106 Ph 1 completed Experimental Human Infection With Neisseria Gonorrhoeae
NCT00786669 VITAC VITAC Ph 1 completed A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
NCT01595529 results posted 09-0103 Ph 2 completed The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"
NCT01949363 12-0025 HHSN272201500007I Ph 1 completed The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study
NCT02708992 15-0031 HHSN272201500006I Ph 1 completed Cefixime / Azithromycin pK Study
NCT01072136 results posted 07-0082 Ph 3 terminated Empiric Therapy of Mucopurulent Cervicitis (MPC)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFIXIME FDA Label Details

Indications & Usage

FDA Label (PDF)

Cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections Otitis Media Pharyngitis and Tonsillitis Acute Exacerbations of Chronic Bronchitis Uncomplicated Gonorrhea (cervical/urethral) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs, cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected t...

Looking for the branded version?

SUPRAX

Full clinical data, patents, trials, and competitive landscape for cefixime.

See SUPRAX

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.